APO RESEARCH · REPORT
Celecoxib
Celecoxib capsules (patent brand name: CELEBREX), is a new generation of non-steroidal anti-inflammatory and analgesic drugs, mainly through the selective inhibition of coX-2 (COX-2) to inhibit the production of prostaglandins, achieve anti-inflammatory and analgesic effects.
Product & engineering
Understand the product.
Celecoxib capsules (patent brand name: CELEBREX), is a new generation of non-steroidal anti-inflammatory and analgesic drugs, mainly through the selective inhibition of coX-2 (COX-2) to inhibit the production of prostaglandins, achieve anti-inflammatory and analgesic effects.
The drug is used to relieve symptoms and signs of osteoarthritis and rheumatoid arthritis in adults and has fewer gastrointestinal side effects than traditional non-steroidal anti-inflammatory drugs.
Selected research
Industry Research
Celecoxib Industry Research Report 2026
Market perspective
Celecoxib capsules (patent brand name: CELEBREX), is a new generation of non-steroidal anti-inflammatory and analgesic drugs, mainly through the selective inhibition of coX-2 (COX-2) to inhibit the production of prostaglandins, achieve anti-inflammatory and analgesic effects.
The drug is used to relieve symptoms and signs of osteoarthritis and rheumatoid arthritis in adults and has fewer gastrointestinal side effects than traditional non-steroidal anti-inflammatory drugs.
Data show that more than 400 million people worldwide are currently affected by joint diseases.
Read the full market overview
The prevalence of osteoarthritis is 17 percent among people aged 40, 62 percent among people over 60 and 80 percent among people over 75.
The number of patients with arthritis in mainland China is more than 10% of the total population, well over 100 million, and the incidence of arthritis increases with age, and the number of patients is still increasing.
At present, the burden of chronic diseases will increase by 40% due to the aging of the population.
As the population ages, anti-inflammatory and anti-rheumatic drugs will enter a phase of rapid growth.
Globally, whether prescription drugs or non-prescription drugs, Xibu is widely used in clinical practice.
At present, the best seller in the international market is Celixib. Celixib market will continue to grow steadily in the next few years.
At present, the global Celecoxib market is basically occupied by Pfizer, which has formed an oligopoly.
It accounted for 63.39% of the global market in 2019.
As of 2019, China relies entirely on Pfizer for celecoxib imports.
Since 2020, some domestic drug companies have been gradually approved by FDA and CFDA. The introduction of celecoxib generic drugs by local companies will break the monopoly of import.
Report Scope
This report quantifies the global Celecoxib market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Celecoxib Market by Company
Pfizer Inc
Teva
Mylan
Apotex
Lupin
Hengrui Medicine
Celecoxib Segment by Type
50mg
100mg
200mg
400mg
Celecoxib Segment by Application
Rheumatoid arthritis
osteoarthritis
Acute pain
Musculoskeletal pain
Other diseases
Celecoxib Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Celecoxib market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Celecoxib and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Celecoxib.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Celecoxib manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Celecoxib by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Celecoxib in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- 50mg
- 100mg
- 200mg
- 400mg
Applications
- Rheumatoid arthritis
- osteoarthritis
- Acute pain
- Musculoskeletal pain
- Other diseases
Companies covered
- Pfizer Inc
- Teva
- Mylan
- Apotex
- Lupin
- Hengrui Medicine
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Celecoxib Market Size (2021-2032)
- 2.2.2 Global Celecoxib Sales (2021-2032)
- 2.2.3 Global Celecoxib Market Average Price (2021-2032)
- 2.3 Celecoxib by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 50mg
- 2.3.3 100mg
- 2.3.4 200mg
- 2.3.5 400mg
- 2.4 Celecoxib by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Rheumatoid arthritis
- 2.4.3 osteoarthritis
- 2.4.4 Acute pain
- 2.4.5 Musculoskeletal pain
- 2.4.6 Other diseases
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Celecoxib Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Celecoxib Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global Celecoxib Revenue of Manufacturers (2021-2026)
- 3.4 Global Celecoxib Average Price by Manufacturers (2021-2026)
- 3.5 Global Celecoxib Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Celecoxib, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Celecoxib, Product Type & Application
- 3.8 Global Manufacturers of Celecoxib, Established Date
- 3.9 Global Celecoxib Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Pfizer Inc
- 4.1.1 Pfizer Inc Company Information
- 4.1.2 Pfizer Inc Business Overview
- 4.1.3 Pfizer Inc Celecoxib Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Pfizer Inc Celecoxib Product Portfolio
- 4.1.5 Pfizer Inc Recent Developments
- 4.2 Teva
- 4.2.1 Teva Company Information
- 4.2.2 Teva Business Overview
- 4.2.3 Teva Celecoxib Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Teva Celecoxib Product Portfolio
- 4.2.5 Teva Recent Developments
- 4.3 Mylan
- 4.3.1 Mylan Company Information
- 4.3.2 Mylan Business Overview
- 4.3.3 Mylan Celecoxib Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Mylan Celecoxib Product Portfolio
- 4.3.5 Mylan Recent Developments
- 4.4 Apotex
- 4.4.1 Apotex Company Information
- 4.4.2 Apotex Business Overview
- 4.4.3 Apotex Celecoxib Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Apotex Celecoxib Product Portfolio
- 4.4.5 Apotex Recent Developments
- 4.5 Lupin
- 4.5.1 Lupin Company Information
- 4.5.2 Lupin Business Overview
- 4.5.3 Lupin Celecoxib Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Lupin Celecoxib Product Portfolio
- 4.5.5 Lupin Recent Developments
- 4.6 Hengrui Medicine
- 4.6.1 Hengrui Medicine Company Information
- 4.6.2 Hengrui Medicine Business Overview
- 4.6.3 Hengrui Medicine Celecoxib Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Hengrui Medicine Celecoxib Product Portfolio
- 4.6.5 Hengrui Medicine Recent Developments
5 Global Celecoxib Market Scenario by Region
- 5.1 Global Celecoxib Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Celecoxib Sales by Region: 2021-2032
- 5.2.1 Global Celecoxib Sales by Region: 2021-2026
- 5.2.2 Global Celecoxib Sales by Region: 2027-2032
- 5.3 Global Celecoxib Revenue by Region: 2021-2032
- 5.3.1 Global Celecoxib Revenue by Region: 2021-2026
- 5.3.2 Global Celecoxib Revenue by Region: 2027-2032
- 5.4 North America Celecoxib Market Facts & Figures by Country
- 5.4.1 North America Celecoxib Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Celecoxib Sales by Country (2021-2032)
- 5.4.3 North America Celecoxib Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Celecoxib Market Facts & Figures by Country
- 5.5.1 Europe Celecoxib Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Celecoxib Sales by Country (2021-2032)
- 5.5.3 Europe Celecoxib Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Celecoxib Market Facts & Figures by Country
- 5.6.1 Asia Pacific Celecoxib Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Celecoxib Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Celecoxib Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Celecoxib Market Facts & Figures by Country
- 5.7.1 South America Celecoxib Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Celecoxib Sales by Country (2021-2032)
- 5.7.3 South America Celecoxib Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Celecoxib Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Celecoxib Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Celecoxib Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Celecoxib Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Celecoxib Sales by Type (2021-2032)
- 6.1.1 Global Celecoxib Sales by Type (2021-2032) & (K Units)
- 6.1.2 Global Celecoxib Sales Market Share by Type (2021-2032)
- 6.2 Global Celecoxib Revenue by Type (2021-2032)
- 6.2.1 Global Celecoxib Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Celecoxib Revenue Market Share by Type (2021-2032)
- 6.3 Global Celecoxib Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Celecoxib Sales by Application (2021-2032)
- 7.1.1 Global Celecoxib Sales by Application (2021-2032) & (K Units)
- 7.1.2 Global Celecoxib Sales Market Share by Application (2021-2032)
- 7.2 Global Celecoxib Revenue by Application (2021-2032)
- 7.2.1 Global Celecoxib Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Celecoxib Revenue Market Share by Application (2021-2032)
- 7.3 Global Celecoxib Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Celecoxib Value Chain Analysis
- 8.1.1 Celecoxib Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Celecoxib Production Mode & Process
- 8.2 Celecoxib Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Celecoxib Distributors
- 8.2.3 Celecoxib Customers
9 Global Celecoxib Analyzing Market Dynamics
- 9.1 Celecoxib Industry Trends
- 9.2 Celecoxib Industry Drivers
- 9.3 Celecoxib Industry Opportunities and Challenges
- 9.4 Celecoxib Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst